Roche Taps Scientific Heavyweight John Reed To Head Early Pharma R&D
This article was originally published in The Pink Sheet Daily
Roche has enlisted John Reed - head of the La Jolla-based Sanford-Burnham Medical Research Institute - to lead the Swiss group’s non-Genentech pharmaceutical R&D efforts.
You may also be interested in...
As NIH funding becomes increasingly scarce, the La Jolla, Calif., research institute will use an anonymously donated gift to emphasize translational projects and take internal risk. Will it deliver returns that sustain the organization?
The acting head of Roche pharma research and early development stepped into the job amid major personnel changes in the pharma organization and the consolidation and streamlining of pRED. He spoke with the “The Pink Sheet” about his group’s priorities and the inevitable short-term hit to research productivity.
AstraZeneca has appointed an experienced biotech and pharmaceuticals executive, Pascal Soriot, to its vacant CEO position, while Roche switches Daniel O'Day from its diagnostics to its pharmaceuticals division.